John Poss had spent 40 years working with troubled companies from every industry before becoming the CEO of GB Sciences Inc., a cutting edge cannabis cultivation and biopharmaceutical research company.
Unfortunately, he quickly learned that there was a chasm between the desire to help and the reality of bringing new medicines to those patients.
According to Poss, cannabis-medicine faces enormous structural impediments. Beyond the innovation-stifling nature of the pharmaceutical industry itself, which routinely requires billions of dollars to bring a new medicine to market, cannabis’ designation as a Schedule 1 drug routinely sparks fear and seriously impedes new research. For example, a basic toxicity test for one of GB Science’s medicines took almost two years to complete because U.S. institutions refused to test any medicine even associated with cannabis.
In Poss’ view cannabis has the unique ability to disrupt and then help fix this broken system because, one, grown on a large scale cannabis has the potential to deliver a wide range of benefits at low cost. And two, while traditional pharmaceuticals are focused on isolating a single molecule, if Poss can help prove the entourage effect, he hopes companies will have to reconsider their approach to include the possibility of multiple parts of a plant working together as a medicine.
Poss is well aware he’s facing an uphill battle, but it’s one he’s completely committed to fighting.
“Our vision is a simple one,” he said. “Putting cannabis based medicine in the hands of patients.”
To hear John Poss speak more about his work on cannabis pharmaceuticals, his drive to democratize medicine, and much more, join us in Los Angeles on July 27 for a day devoted to exploring the intersection of cannahemp medical research and manufacturing technology.